Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

[1]  N. Hahn.  Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study , 2021, Neurology.

[2]  K. Makar,et al.  WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.

[3]  G. Cutter,et al.  Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis , 2021, JAMA neurology.

[4]  E. Chu,et al.  Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies , 2021, Clinical chemistry and laboratory medicine.

[5]  A. Wallach,et al.  The presence of SARS-CoV2 antibodies in MS patients , 2021, Multiple Sclerosis and Related Disorders.

[6]  M. Sormani,et al.  Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.

[7]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[8]  J. Thornton,et al.  Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab , 2020, Multiple Sclerosis and Related Disorders.

[9]  A. Bar-Or,et al.  Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis , 2018, Neurology.

[10]  Ashutosh Kumar Singh,et al.  Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis , 2015, Neurology.

[11]  J. Kelton,et al.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. , 2013, Blood.